01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – £5.1m RSV Human Challenge Study Contract Win November 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has signed a £5.1m contract with a biopharmaceutical company to test its Investigational Medicinal Product (IMP) using hVIVO’s respiratory syncytial virus (RSV) Human Challenge Study Model. The study is due to commence in H2 2022, with the revenue from the…

Continue reading

Open Orphan #ORPH – £7.5m Human Challenge Study Contract March 26, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has entered into a contract with a  biotechnology company to run a human viral challenge study for a respiratory syncytial virus (“RSV”) prophylactic and treatment.   This US biotechnology company is developing a product for the prevention and…

Continue reading

Open Orphan #ORPH – Major New Contract Signed With US Biotech Company for RSV Human Study & CEO Trevor Phillips to Step Down. – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce the signing of a new contract with a US biotechnology Company for the provision of a respiratory syncytial virus (RSV) human challenge study. Highlights: Challenge study projected to deliver £3.5 million in revenue in 2020…

Continue reading

Open Orphan tip of the year update on mega contract win March 6, 2020 – Posted in: Open Orphan (ORPH)

by Tom Winnifrith Open Orphan (ORPH) was one of my tips of the year at a 4.6p offer. The shares are now 5.5p bid – the recent market sell off hitting it like nearly all other stocks. But the news today of a contract potentially worth £10 million plus really does slam home the message of how cheap the shares are. There are currently no broker forecasts out there but that is something that I…

Continue reading

Irish Times – Open Orphan seals deal that could net more than €11.6m – Posted in: Open Orphan (ORPH)

by Colin Gleeson Dublin-listed pharma group announces contract with European biotech company Dublin-listed pharma services company Open Orphan has announced the signing of a new contract with a European biotech company that could yield it more than £10 million in revenue this year. Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed the Irish stock exchange of the deal for the provision of an respiratory syncytial virus (RSV) human challenge study on Friday. The…

Continue reading